-$0.16 EPS Expected for Abeona Therapeutics Inc (ABEO) This Quarter

Wall Street brokerages expect Abeona Therapeutics Inc (NASDAQ:ABEO) to post earnings of ($0.16) per share for the current quarter, according to Zacks. Five analysts have issued estimates for Abeona Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.20) and the highest estimate coming in at ($0.05). Abeona Therapeutics reported earnings per share of ($0.21) in the same quarter last year, which suggests a positive year-over-year growth rate of 23.8%. The business is scheduled to report its next quarterly earnings results on Tuesday, August 21st.

On average, analysts expect that Abeona Therapeutics will report full year earnings of ($0.71) per share for the current financial year, with EPS estimates ranging from ($0.89) to ($0.34). For the next fiscal year, analysts expect that the company will post earnings of ($0.67) per share, with EPS estimates ranging from ($0.98) to ($0.29). Zacks’ EPS averages are a mean average based on a survey of research firms that cover Abeona Therapeutics.

Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings data on Monday, May 14th. The biopharmaceutical company reported ($0.18) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.01. Abeona Therapeutics had a negative net margin of 939.83% and a negative return on equity of 23.57%. The firm had revenue of $2.60 million during the quarter, compared to analysts’ expectations of $0.27 million.

A number of equities analysts have commented on the stock. Maxim Group set a $35.00 price objective on shares of Abeona Therapeutics and gave the stock a “buy” rating in a research report on Monday, May 14th. Seaport Global Securities assumed coverage on shares of Abeona Therapeutics in a research report on Tuesday, June 5th. They set a “buy” rating and a $29.00 price objective for the company. Cantor Fitzgerald set a $36.00 price objective on shares of Abeona Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, May 22nd. ValuEngine raised shares of Abeona Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, June 1st. Finally, BidaskClub raised shares of Abeona Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, June 28th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have assigned a buy rating to the stock. Abeona Therapeutics has a consensus rating of “Buy” and an average price target of $28.30.

Abeona Therapeutics opened at $13.95 on Friday, MarketBeat reports. Abeona Therapeutics has a one year low of $7.01 and a one year high of $22.75. The firm has a market cap of $669.37 million, a price-to-earnings ratio of -21.14 and a beta of 1.26.

Several institutional investors have recently made changes to their positions in the company. Fortaleza Asset Management Inc. bought a new stake in shares of Abeona Therapeutics in the second quarter valued at about $104,000. Mesirow Financial Investment Management Inc. bought a new stake in shares of Abeona Therapeutics in the second quarter valued at about $348,000. Millennium Management LLC boosted its position in shares of Abeona Therapeutics by 2,357.3% in the first quarter. Millennium Management LLC now owns 916,256 shares of the biopharmaceutical company’s stock valued at $13,148,000 after acquiring an additional 878,969 shares during the period. Nexthera Capital LP bought a new stake in shares of Abeona Therapeutics in the first quarter valued at about $5,302,000. Finally, Sabby Management LLC bought a new stake in shares of Abeona Therapeutics in the first quarter valued at about $187,000. 69.11% of the stock is owned by institutional investors.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

Further Reading: Book Value Per Share – BVPS

Get a free copy of the Zacks research report on Abeona Therapeutics (ABEO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply